|
Report Date : |
15.02.2014 |
IDENTIFICATION DETAILS
|
Name : |
TAKEDA PHARMA S.A. |
|
|
|
|
Formerly Known As : |
NYCOMED SA |
|
|
|
|
Registered Office : |
Tronador 4890 piso 7 Buenos Aires City |
|
|
|
|
Country : |
Argentina |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
24.03.1960 |
|
|
|
|
Legal Form : |
Public Limited Company |
|
|
|
|
Line of Business : |
Subject is engaged in the production, marketing, import and export of
drugs and medicinal products for human use and consumption. |
|
|
|
|
No. of Employees : |
160 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 135900 |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
Argentina |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
ARGENTINA - ECONOMIC OVERVIEW
Argentina benefits from rich
natural resources, a highly literate population, an export-oriented
agricultural sector, and a diversified industrial base. Although one of the world's
wealthiest countries 100 years ago, Argentina suffered during most of the 20th
century from recurring economic crises, persistent fiscal and current account
deficits, high inflation, mounting external debt, and capital flight. A severe
depression, growing public and external indebtedness, and an unprecedented bank
run culminated in 2001 in the most serious economic, social, and political
crisis in the country's turbulent history. Interim President Adolfo RODRIGUEZ
SAA declared a default - at the time the largest ever - on the government's
foreign debt in December of that year, and abruptly resigned only a few days
after taking office. His successor, Eduardo DUHALDE, announced an end to the
peso's decade-long 1-to-1 peg to the US dollar in early 2002. The economy
bottomed out that year, with real GDP 18% smaller than in 1998 and almost 60%
of Argentines under the poverty line. Real GDP rebounded to grow by an average
8.5% annually over the subsequent six years, taking advantage of previously
idled industrial capacity and labor, an audacious debt restructuring and
reduced debt burden, excellent international financial conditions, and
expansionary monetary and fiscal policies. Inflation also increased, however,
during the administration of President Nestor KIRCHNER, which responded with
price restraints on businesses, as well as export taxes and restraints, and
beginning in 2007, with understating inflation data. Cristina FERNANDEZ DE
KIRCHNER succeeded her husband as President in late 2007, and the rapid economic
growth of previous years began to slow sharply the following year as government
policies held back exports and the world economy fell into recession. The
economy in 2010 rebounded strongly from the 2009 recession, but has slowed
since late 2011 even as the government continued to rely on expansionary fiscal
and monetary policies, which have kept inflation in the double digits. The
government expanded state intervention in the economy throughout 2012. In May
the Congress approved the nationalization of the oil company YPF from Spain's
Repsol. The government expanded formal and informal measures to restrict
imports during the year, including a requirement for pre-registration and
pre-approval of all imports. In July the government also further tightened
currency controls in an effort to bolster foreign reserves and stem capital
flight.
|
Source
: CIA |
TAKEDA PHARMA S.A.
CUIT NRO. 30.50160299.6
CREATED IN 1960. GOOD COMMERCIAL DEVELOPMENT. BALANCE SHEET AT
31/12/2012. COMPLIANCE ORDERED. FIT FOR CREDITS.
> DRUGS AND MEDICAL PRODUCTS
> PROCESSING
> MARKETING
> IMPORT
> EXPORT
LEGAL FORM: PUBLIC LIMITED COMPANY
CREATED: 24.03.1960
REGISTERED R.P.C. 15.02.1961
I.G.P.J. REGISTRO NRO 10.651
DURATION: 24.03.1960
END OF FISCAL YEAR: 31.12.
Afip: nro. 20 Defensa 135 Subsuelo.
LUCAS RUDOLPH (ACCOUNTANT)
Operativa address: Tronador 4890
piso 7 Buenos Aires City, Republic of Argentina.
Phone: 54.11.4547.4700
Fax. 54.11.4546.4784
E-mail: mailentry@takeda.com
PRESIDENT:
JACK KASSIS MADOSI
VICEPRESIDENT: JUAN CARLOS BERISSO
DIRECTOR:
NORBERT OPPITZ
* Those who have the use of the firm name. -
Social capital: $ 63.550.537.-
It is in a position to state that these businesses were launched by the
company in its LIPRANDI SRL established early in Cesar Diaz 5053 of the City of
Buenos Aires.
Its action is polongo until 1960, it is organized as a continuation BYK
LIPRANDI SACI Street Delgado 1565 located in that same plaza, which change the denomination
in 1997 by BYK ARGENTINA SA .
To the above should be added that in July 2002 a new change in his denomination
by ALTANA PHARMA SA
It should be noted that ALTANA PHARMA is an international pharmaceutical group
with over 30 subsidiaries with over 30 subsidiaries located in Europe, North
and South America, Asia, South Africa and Australia, with ALTANA PHARMA AG and
ALTANA AG's pharmaceutical division.
Later the company changed the business name to Nycomed SA up to the current
TAKEDA PHARMA SA –
Below we quote figures Balances to 31.12.2011 and 31.12.2012 in pesos of
our country.
Leaving clarified that changed after the closing date 31.12.2012 change to
Balance as of March 31.
31.12.2011
31.12.2012
----------- -----------
CASH INVESTMENTS
CREDITS AND OTHER
21.902.182 25.284.575
INVENTORIES 27.563.632 26.741.557
ASSETS CURRENT
49.465.814 52.026.132
ASSETS NON-CURRENT
3.433.262 3.764.550
TOTAL ASSETS
52.899.076 55.790.682
DEBS
25.781.227 28.845.883
SALARIES AND
SOCIAL CHARGES
4.723.375
4.396.570
LIABILITIES CURRENT
30.504.602 33.242.453
LIABILITIES NON-CURRENT
1.209.956 1.315.306
LIABILITIES
31.714.558 34.557.759
NET WORTH
21.184.518 21.232.923
TOTAL GENERAL
52.899.076 55.790.682
NET SALES
133.169.018 33.461.904
COST OF SALES - 60.179.996 - 14.711.121
GAIN (LOSS) GROSS 72.989.022
18.750.783
EXPENSES COMERCIALIZATION - 57.598.875
- 14.108.332
EXPENSES ADMINISTRATION - 11.988.419 - 2.754.453
SUB TOTAL
3.401.728 1.887.998
OTHER EXPENSES AND INCOMES - 1.762.959
1.839.593
FINAL RESULT
1.638.769 48.405
The society is dedicated to the production, marketing, import and export
of drugs and medicinal products for human use and consumption.
Account paa it with advanced technology and the latest generation which has
been developing activities.
HABITUAL SUPPLIERS:
-------------------
> BROBEL S.A.
> TALLERES GRAFICOS MORALES S..
> UNIFARMA S.A.
FOREIGN TRADE:
--------------
In the last twelve months, it has made specific imports by u$s.3.710.443
according to the following detail:France, Switzerland, Spain and others.
TRADEMARKS:
-----------
ARCADIN
BILUFLAT
CARQUEJA TROP
HEPATALGINA
KRONO FIBRAS
MARICINA
NERGIZE
BACTIORAL
DILANTEX
LAKE
MEREBRAL
TOPILAX.
* 160 EMPLOYEES.
Deposit: Parque Industrial de Pilar, Ruta Nac. 8 km 60 Pilar, Province
of Buenos Aires.
* CITIBANK N.
* SANTANDER RIO
* ICBC BANK
CREDIT RISK:
NOVEMBER 2013
CITIBANK....... 7.581.500
ICBC........... 64.400
SITUATION 1: NORMAL.
INSURANCE:
----------
LIBERTY S.A.
The company is normally fulfilling its obligations and no complaints
have been heard regarding payments.
There is no registration of legal suits, petitions in bankrutpcy or closed
banking accounts in the name of Subject or its principals.
* PERFORMANCE WITHOUT OBJECTION
According to the information, we consider it is acceptable to deal with
the subject company for amounts moderated with securities in relation with the
amounts granted.
* FIT FOR CREDITS.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.28 |
|
|
1 |
Rs.103.67 |
|
Euro |
1 |
Rs.85.18 |
INFORMATION DETAILS
|
Report Prepared
by : |
NNA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.